H
Harriet M. Kluger
Researcher at Yale University
Publications - 309
Citations - 19633
Harriet M. Kluger is an academic researcher from Yale University. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 61, co-authored 269 publications receiving 15836 citations. Previous affiliations of Harriet M. Kluger include University of Michigan & University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian,Mario Sznol,David F. McDermott,Harriet M. Kluger,Richard D. Carvajal,William H. Sharfman,Julie R. Brahmer,Donald P. Lawrence,Michael B. Atkins,John D. Powderly,Philip D. Leming,Evan J. Lipson,Igor Puzanov,David Smith,Janis M. Taube,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Drew M. Pardoll,Jeffrey A. Sosman,F. Stephen Hodi +20 more
TL;DR: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation.
Journal ArticleDOI
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Michael Krauthammer,Yong Lin Kong,Byung Hak Ha,Perry Evans,Antonella Bacchiocchi,James P. McCusker,Elaine Cheng,Matthew J. Davis,Gerald Goh,Murim Choi,Stephan Ariyan,Deepak Narayan,Ken Dutton-Regester,Ken Dutton-Regester,Ana Capatana,Edna C. Holman,Marcus Bosenberg,Mario Sznol,Harriet M. Kluger,Douglas E. Brash,David F. Stern,Miguel A. Materin,Roger S. Lo,Shrikant Mane,Shuangge Ma,Kenneth K. Kidd,Nicholas K. Hayward,Richard P. Lifton,Joseph Schlessinger,Titus J. Boggon,Ruth Halaban +30 more
TL;DR: In this article, the authors characterized the mutational landscape of melanoma, the form of skin cancer with the highest mortality rate, by sequencing the exomes of 147 melanomas and found that sun-exposed melanomas had markedly more ultraviolet-like C>T somatic mutations compared to sun-shielded acral, mucosal and uveal melanomas.
Journal ArticleDOI
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul Nghiem,Shailender Bhatia,Evan J. Lipson,Ragini R. Kudchadkar,Natalie J. Miller,Lakshmanan Annamalai,Sneha Berry,Elliot Chartash,Adil Daud,Steven P. Fling,Philip Friedlander,Harriet M. Kluger,Holbrook E Kohrt,Lisa Lundgren,Kim Margolin,Alan Mitchell,Thomas Olencki,Drew M. Pardoll,Sunil Reddy,E. Shantha,William H. Sharfman,Elad Sharon,Lynn Shemanski,Michi M. Shinohara,Joel C. Sunshine,Janis M. Taube,John A. Thompson,John A. Thompson,Steven M. Townson,Jennifer H. Yearley,Suzanne L. Topalian,Martin A. Cheever,Martin A. Cheever +32 more
TL;DR: First-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56% and effectiveness was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing.
Journal ArticleDOI
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg,Scott N. Gettinger,Amit Mahajan,Anne C. Chiang,Roy S. Herbst,Mario Sznol,Apostolos John Tsiouris,Justine V. Cohen,Alexander O. Vortmeyer,Lucia B. Jilaveanu,James B. Yu,Upendra P. Hegde,Stephanie Speaker,Matthew Madura,Amanda Ralabate,Angel Rivera,Elin Rowen,Heather Gerrish,Xiaopan Yao,Veronica Chiang,Harriet M. Kluger +20 more
TL;DR: Pembrolizumab shows activity in brain metastases in patients with melanoma or non-small-cell lung cancer with an acceptable safety profile, which suggests that there might be a role for systemic immunotherapy in Patients with untreated or progressive head metastases.
Journal ArticleDOI
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.
Keith S. Hoek,David L. Rimm,Kenneth R. Williams,Hongyu Zhao,Stephan Ariyan,Aiping Lin,Harriet M. Kluger,Aaron Berger,Elaine Cheng,E. Sergio Trombetta,Terence Wu,Michio Niinobe,Kazuaki Yoshikawa,Gregory E. Hannigan,Ruth Halaban +14 more
TL;DR: A comprehensive view of changes in advanced melanoma relative to normal melanocytes is provided and new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients are revealed.